The following is a summary of “Increased Expression of Serum Monocyte Chemoattractant Protein-1, Chemokine (C-C motif) Ligand 3, and Interleukins in Patients With Vitiligo,” published in the March 2024 issue of Dermatology by Zhao, et al.
For a study, researchers sought to identify potential markers for the active stage of vitiligo progression by comparing serum levels of selected cytokines in patients with vitiligo (active and stable) and healthy controls.
Serum samples were collected from 30 healthy controls and 60 patients with vitiligo (30 with active disease and 30 with stable disease) between May 2017 and December 2018. The levels of monocyte chemoattractant protein (MCP)-1, chemokine (C-C motif) ligand (CCL) 3, CCL5, CCL21, interleukin (IL)-6, and IL-17 were measured using enzyme-linked immunosorbent assay (ELISA). Statistical analysis was performed using the Kruskal-Wallis H test and Mann-Whitney U test.
The study observed significantly elevated serum levels of MCP-1, CCL3, IL-6, and IL-17 in patients with vitiligo compared to healthy controls (P < 0.01). Furthermore, among patients with vitiligo, IL-17 levels were notably higher in those with active disease than those with stable disease (P < 0.01). Following 3 months of treatment, there was no significant difference in serum IL-17 levels among patients with active vitiligo compared to pre-treatment levels (P = 0.526). However, after 6 months of treatment, we observed a significant decrease in serum IL-17 levels (P < 0.01).
The study suggested that serum IL-17 levels could serve as a potential marker for disease activity in patients with vitiligo, providing valuable guidance for clinical treatment decisions.
Reference: journals.lww.com/ijdv/fulltext/2024/03000/increased_expression_of_serum_monocyte.7.aspx